Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Ryvu Therapeutics SA
RVURyvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. The company has a research collaboration with Ncage Therapeutics Limited to develop next-generation antibody-drug conjugate (ADC) platform. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland. Address: Leona Henryka Sternbacha 2, Kraków, Poland, 30-394
Analytics
Objectif de Cours de WallStreet
323.1 PLNRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés RVU
Analyse des dividendes RVU
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes RVU
Valorisation des titres RVU
financières RVU
Résultats | 2019 | Dynamique |